Innovative Diagnosis and Therapy in LDLT Patients With High-risk Hepatocellular Carcinoma

High Risk of Recurrence Clinical Trial

Official title:

Innovative Diagnosis and Therapy in LDLT Patients With High-risk Hepatocellular Carcinoma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06327269
• Other study ID #: MOHW111-TDU-B-221-114009
• Status: Recruiting
• Phase: Early Phase 1
• Start date: April 1, 2021
• Est. completion date: December 2026

Study information

• Verified date: March 2024
• Source: Chang Gung Memorial Hospital
• Contact: Chih-Che Lin, Ph.D
• Phone: +88677317123
• Email: chihchelin[@]cgmh.org.tw
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The challenge of LDLT to HCC is that tumors with a high risk of recurrence have a high rate of recurrence after liver transplantation, and there is no appropriate treatment to prevent HCC recurrence after transplantation in these patients. Using the advance proton therapy or yttrium 90 as a more aggressive down-staging therapy may contribute to change tumor behavior. It can be used to get a better treatment response and tumor necrosis before LDLT. As a result, it will improve recurrence-free survival and overall survival rate, especially in high-risk groups. In addition, lenvatinib is approved for using in patients with advanced liver cancer because its overall survival rate is not less than sorafenib in clinical trials. A new generation of targeted therapies will be applied to adjuvant therapy after LDLT.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 40
• Est. completion date: December 2026
• Est. primary completion date: December 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria

• Targeted therapy is acceptable within 1-2 months after liver transplantation.

• Immunosuppressive regimen consists of calcineurin inhibitor, mycophenolate mofetil and sirolimus.

• All male and female participants must take reliable contraceptive measures during the trial and within four weeks after the end of the trial.

• The definition of high-risk patients:

• The PET scan is positive before LDLT;

• Tumors beyond USCF criteria

• Poorly-differentiated tumor;

• The patients who has poor AFP response (<15%)or AFP>400 ng/ml after LRT after conventional LRT (RFA?PEI or TACE)

Exclusion Criteria

• Life expectancy is less than 3 months

• Patients are with other malignant tumors simultaneously.

• Patients are anaphylaxis to the inactive ingredients of lenvatinib or drugs.

• Pregnant or lactating women (Female participants need pregnancy test within 7 days before treatment).

• Preoperative history of severe cardiovascular disease: congestive heart failure > NYHA grade 2; active coronary heart disease (myocardial infarction occurred within 6 months before entry into the study); severe arrhythmia requiring antiarrhythmic treatment (allowable use of beta-blockers or digoxin); uncontrolled hypertension.

• History of HIV infection.

• Severe clinical active infections (> NCI-CTCAE version 3.0).

• Epilepsy patients requires medication (e.g. steroids or antiepileptic drugs).

• Patients with kidney diseases requires renal dialysis.

• Drug abuse, medical symptoms, mental illness or social status that may interfere with participants' participation in research or evaluation of research results.

• Patients who could not swallow oral drugs, such as those with severe upper gastrointestinal obstruction and need gastric tube feeding.

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Hepatocellular
• High Risk of Recurrence
• Recurrence

Intervention

Drug:
• Lenvatinib 10 mg
Lenvatinib would be used on patients with advanced liver cancer after Liver transplantation as an adjuvant treatment.

Locations

Country	Name	City	State
Taiwan	Department of Surgery	Kaohsiung

Sponsors (2)

Lead Sponsor	Collaborator
Chang Gung Memorial Hospital	Ministry of Health and Welfare, Taiwan

Country where clinical trial is conducted

Taiwan, 

References & Publications (1)

Han B, Ding H, Zhao S, Zhang Y, Wang J, Zhang Y, Gu J. Potential Role of Adjuvant Lenvatinib in Improving Disease-Free Survival for Patients With High-Risk Hepatitis B Virus-Related Hepatocellular Carcinoma Following Liver Transplantation: A Retrospective — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Recurrence-free survival with adjuvant therapy	Lenvatinib treatment may prolong the recurrence-free survival rate after LDLT.	2 years